8月8日 - ** 疗法开发商Capricor Therapeutics CAPR.O股价盘前上涨3.22%，报8.33美元
** 该公司表示，已计划与美国食品及药物管理局（FDA）举行会议，讨论其细胞疗法治疗杜氏肌营养不良症相关心肌病（一种肌肉疾病）的监管路径。
** 为配合此次会议，公司已将第二季度财报的发布时间从 8 月 12 日改为 8 月 11 日。
** 美国食品和药物管理局（FDA）于 7 月拒绝了 (link) 批准 Deramiocel，称该疗法不符合疗效要求，并要求提供更多数据。
** 截至上次收盘，股价累计下跌 41.5
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.